Simple Summary Tumors from pancreatic cancer contain many types of cells (such as
immune cells and fibroblasts) in addition to the cancer cells. Using targeted drugs to disrupt …

Gastric cancer (GC) is a severe malignancy, accounting for the third most common cancer
death worldwide. Despite the development of chemo-radiation therapy, there has not been …

MALT lymphoma is an extranodal B-cell lymphoma of the marginal zone of mucosa-
associated lymphoid tissue (MALT), caused by malignant transformation of B-cells in the …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall
survival of 11%. The disease is usually diagnosed at advanced stages, and systemic …

There has been an increasing use of master protocols in oncology clinical trials because of
its efficiency to accelerate cancer drug development and flexibility to accommodate multiple …

Background Programmed death-ligand-1 (PD-L1) molecule is a well-known predictive
biomarker for the efficacy of immune checkpoint inhibitors (ICIs) in several cancers. Present …

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related
mortality, with cytotoxic chemotherapy still the mainstay of treatment. Beyond effective …

Purpose: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of
palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma …

Live biotherapeutics (LBP) are a novel strategy for delivering anticancer protein therapeutics
while circumventing the traditional limitations associated with conventional drug delivery …

Regardless of success of immunotherapy in other tumor types, pancreatic ductal
adenocarcinoma (PDAC) has remained largely resistant to the benefit of immunotherapy …